

Contents

Part I Cortico-Subcortical Circuits and Parkinson's Disease

- 1 **Leading Toward a Unified Cortico-basal Ganglia Functional Model** 3
Shannon R. Blume and Kuei Y. Tseng
- 2 **Modeling Parkinson's Disease: 50 Years Later** 23
Gloria E. Meredith and Kuei Y. Tseng

Part II Physiological Studies of the Cortico-subcortical Dynamics and Parkinson's Disease

- 3 **Phasic Dopaminergic Signaling: Implications for Parkinson's Disease** 37
Stefan G. Sandberg and Paul E.M. Phillips
- 4 **Striatal Dendritic Adaptations in Parkinson's Disease Models** 55
Michelle Day and D. James Surmeier
- 5 **Diversity of Up-State Voltage Transitions During Different Network States** 73
Nicolas Vautrelle, Luis Carrillo-Reid, and José Bargas
- 6 **The Corticostriatal Pathway in Parkinson's Disease** 87
Nigel S. Bamford and Carlos Cepeda
- 7 **Cholinergic Interneuron and Parkinsonism** 105
Dario Cuomo, Paola Platania, Giuseppina Martella, Graziella Madeo, Giuseppe Sciamanna, Annalisa Tassone and Antonio Pisani
- 8 **Basal Ganglia Network Synchronization in Animal Models of Parkinson's Disease** 117
Judith R. Walters and Debra A. Bergstrom

9	Converging into a Unified Model of Parkinson's Disease Pathophysiology	143
	Camila L. Zold, Mariano Belluscio, Fernando Kasanetz, Pablo E. Pomata, Luis A. Riquelme, Francois Gonon, and Mario Gustavo Murer	
10	The Corticostriatal Transmission in Parkinsonian Animals: In Vivo Studies	157
	Bérangère Ballion, Nicolas Mallet, Catherine Le Moine, Mario Gustavo Murer, and Francois Gonon	
11	Striatal Nitric Oxide–cGMP Signaling in an Animal Model of Parkinson's Disease	171
	Anthony R. West, Stephen Sammut, and Marjorie A. Ariano	
12	Dopamine–Endocannabinoid Interactions in Parkinson's Disease	185
	Sarah McCallum and Joseph F. Cheer	
13	Glutamate Plasticity in an Animal Model of Parkinson's Disease	207
	Charles K. Meshul	
 Part III Computational Analyses of the Cortico-Subcortical Dynamics and Parkinson's Disease		
14	Neuromodulation and Neurodynamics of Striatal Inhibitory Networks: Implications for Parkinson's Disease	233
	Tomomi Shindou, Gordon W. Arbuthnott, and Jeffery R. Wickens	
15	Dopaminergic Modulation of Corticostriatal Interactions and Implications for Parkinson's Disease	245
	John A. Wolf and Jason T. Moyer	
 Part IV Neurobiology and Pathophysiology of Parkinson's Disease		
16	Pathogenesis of Oxidative Stress and the Destructive Cycle in the Substantia Nigra in Parkinson's Disease	261
	Emilio Fernández-Espejo	
17	Regulation of G-Protein-Coupled Receptor (GPCR) Trafficking in the Striatum in Parkinson's Disease	273
	Marie-Laure Martin-Negrier, Céline Guigoni, Bertrand Bloch, and Erwan Bézard	

18	Atypical Parkinsonism in the French West Indies: The Plant Toxin Annonacin as a Potential Etiological Factor	283
	Annie Lannuzel and Patrick Pierre Michel	
19	Cognitive Deficits in Parkinson's Disease.	291
	Eliana Roldan Gerschovich and Kuei Y. Tseng	
Part V Pharmacological and Non-Pharmacological Treatments in Parkinson's Disease		
20	Dopamine Replacement Therapy in Parkinson's Disease: Past, Present and Future	309
	M.A. Cenci and P. Odin	
21	Molecular, Cellular and Electrophysiological Changes Triggered by High-Frequency Stimulation of the Subthalamic Nucleus in Animal Models of Parkinson's Disease.	335
	Paolo Gubellini and Pascal Salin	
22	Surgical Strategies for Parkinson's Disease Based on Animal Model Data: <i>GPe</i> and <i>STN</i> Inactivation on Various Aspects of Behavior (Motor, Cognitive and Motivational Processes)	371
	Christelle Baunez	
23	Antidromic Cortical Activity as the Source of Therapeutic Actions of Deep Brain Stimulation.	393
	Gordon W. Arbuthnott, Cyril Dejean, and Brian Hyland	
24	Cell-Based Replacement Therapies for Parkinson's Disease	405
	Emilio Fernández-Espejo and Isabel Liste	
	Index	433